SCS: Effect of Spinal Cord Stimulation on Pain Thresholds and Sensory Perception in Chronic Pain Patients.

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01137617
Collaborator
(none)
19
1
78.7
0.2

Study Details

Study Description

Brief Summary

The purpose of this study is to better understand how the Spinal Cord Stimulator works in relieving chronic pain.

The investigators are asking subject to take part in this study because who are chronic pain patients who already have a Spinal Cord Stimulator (SCS) in place.

The investigators hypothesize that chronic pain patients will have higher heat pain threshold and heat pain tolerance over the painful areas with the SCS on.

QST (Quantitative Sensory Testing, a heat/cold simulation test) might be an objective helpful tool for prudent patient selection for an expensive and invasive procedure for future SCS placement.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Sixty subjects who already have an implanted SCS device for pain management at the MGH Center for Pain Medicine and other Partners affiliated pain centers will be enrolled.

    Inclusion Criteria:
    1. Subject is 18 years or older.

    2. Subject has an SCS device implanted for at least one month for pain control. This requirement is set to ensure that the subject becomes familiarized with the therapy and has recovered from the surgical implantation of the SCS device.

    Exclusion Criteria:
    1. Subject has neurological disease or a condition causing sensory deficit to the painful area.

    2. Subject had recent therapy that may influence QST results, e.g., neuroablative procedure within two-months.

    3. Subjects who are unable to travel to the study center.

    It will be a one time outpatient visit study, which will include the following:
    1. Brief pain history and Neurological examination
    • Medical History (including medication use);

    • Pain location, intensity, character and if known, etiology, duration;

    • Maps of pain locations and paresthesia locations;

    • Sensory neurological examination (e.g., alcohol swab, cotton swab, pinprick and vibration);

    • A check on routine vital signs (blood pressure, pulse, pulse oximetry).

    1. QST will include the following:
    • Warm sensation, heat pain threshold, heat pain tolerance and wind-up. A cut-off of 53°C for heat will be preset to avoid tissue damage.

    • QST will be done on two areas; painful area and non-painful area without paresthesia with the SCS turned off.

    • Subject will then turn on SCS and a repeat QST will be performed on the painful and non-painful areas.

    • QST tests will be performed in a quiet room at temperature 25º 2° C. The time and duration of the QST tests will be recorded.

    QST will be performed at least 4 hours and no later than 6 hours after the last dose of long acting opioid and after last SCS on time. In this way the investigators will try to avoid recording possible end dose withdrawal and provide sufficient time for the subject to return to baseline for their SCS therapy.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    19 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Cross-Sectional
    Official Title:
    Effect of Spinal Cord Stimulation on Pain Thresholds and Sensory Perception in Chronic Pain Patients.
    Study Start Date :
    Jun 1, 2010
    Actual Primary Completion Date :
    Aug 1, 2011
    Actual Study Completion Date :
    Dec 20, 2016

    Outcome Measures

    Primary Outcome Measures

    1. Warm Sensation (WS) Threshold- Pain Site [WS threshold is assessed once at Visit 1]

      WS threshold is a type of Quantitative Sensory Test (QST). A contact thermode was attached to the subject's painful area that has SCS coverage. The thermode increased by 1°C/sec from a baseline of 32°C. Subjects were instructed to stop stimulation when they first perceived a warm sensation. Subjects performed this test with their SCS off and again with their SCS on.

    2. Heat Pain (HP) Threshold- Pain Site [HP threshold is assessed once at Visit 1]

      Heat Pain threshold is a type of QST. A contact thermode was attached to the subject's painful area that has SCS coverage. The thermode increased by 1°C/sec from a baseline of 32°C. Subjects were instructed to stop the stimulation when pain was first detected. Subjects performed this test with their SCS off and again with their SCS on.

    3. Heat Pain Tolerance- Pain Site [Heat Pain Tolerance is assessed once at Visit 1]

      Heat Pain threshold is a type of QST. A contact thermode was attached to the subject's painful area that has SCS coverage. The thermode increased by 1°C/sec from a baseline of 32°C. Subjects were instructed to stop the stimulation when pain was no longer tolerable. Subjects performed this test with their SCS off and again with their SCS on.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Subject is 18 years or older.

    • Subject has an SCS device implanted for at least one month for pain control. This requirement is set to ensure that the subject becomes familiarized with the therapy and has recovered from the surgical implantation of the SCS device.

    Exclusion Criteria:
    • Subject has neurological disease or a condition causing sensory deficit to the painful area.

    • Subject had recent therapy that may influence QST results, e.g., neuroablative procedure within two-months.

    • Subjects who are unable to travel to the study center.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 MGH Center for Translational Pain Research Boston Massachusetts United States 02114

    Sponsors and Collaborators

    • Massachusetts General Hospital

    Investigators

    • Principal Investigator: Shihab Ahmed, MD, Massachusetts General Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jianren Mao, MD, PhD, Principal Investigator, Massachusetts General Hospital
    ClinicalTrials.gov Identifier:
    NCT01137617
    Other Study ID Numbers:
    • 2010P 000425
    First Posted:
    Jun 4, 2010
    Last Update Posted:
    Jul 22, 2020
    Last Verified:
    Jul 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jianren Mao, MD, PhD, Principal Investigator, Massachusetts General Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 22, 2020